Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROS: Low-dose deferasirox for oxidative stress in sickle cell disease
2020-004995-17Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in sickle cell disease (SCD) and Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety of low-dose deferasirox, Efficacy on point of sickling and 1 more. Started Mar 2021; status: completed.
02
Drugs
deferasirox
03
Conditions
sickle cell disease (SCD)Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia)
Beyond the preview
Go deeper on 2020-004995-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004995-17.